Cancer - Flare Therapeutics Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05929235

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Drug

FX-909

Condition

Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma